What is Cagrilintide?

An investigational long-acting amylin analog; CagriSema combines it with semaglutide.

Open the Cagrilintide reconstitution calculator

Cagrilintide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

44 registered trials · 13 indexed papers · 49 human / 17 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Cagrilintide is described as an investigational amylin analog being studied for weight management. It is not a GLP-1 drug, and it is not the same thing as CagriSema, which combines cagrilintide with semaglutide.

As of October 2026, FDA is described as identifying cagrilintide as unapproved and as saying it cannot be used in compounding under federal law.

Mechanism (as described)

  • Amylin is a pancreatic hormone involved in feeling full after eating. Cagrilintide was designed as a longer-acting analog to study sustained appetite and body-weight effects, and its development also addressed native amylin’s stability problems.
  • Laboratory receptor studies describe it, also called AM833, as an agonist at amylin and calcitonin receptors. That differs from semaglutide’s GLP-1 receptor activity; combining the two is described as intended to engage complementary pathways.
  • A second source describes a synthetic, long-acting amylin analog modified for stability and studied for activity at amylin-responsive receptor complexes formed by the calcitonin receptor and receptor activity-modifying proteins (RAMPs).

Evidence (as described)

  • Human trial evidence exists, including a phase 2 trial and the later REDEFINE 1 trial. Trial results do not make an online research vial an approved medicine.
  • A result reported with CagriSema cannot be attributed to cagrilintide alone, and a self-mixed combination is described as not automatically equivalent to the trial formulation.

Registered human trials (44)

TrialPhaseStatusYearEnrolled
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesPhase 3recruiting202680
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsPhase 1recruiting2026114
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightPhase 3recruiting2026460
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightPhase 3recruiting20262500
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaPhase 3recruiting2026210
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightPhase 1completed202650
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightPhase 3recruiting2026285
A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesPhase 2withdrawn2026
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightPhase 3withdrawn2026
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityPhase 1recruiting2026234
A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityPhase 1recruiting2026120
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)Phase 1recruiting2026100
A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObesePhase 1recruiting2026100
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintidePhase 3active not recruiting2025330
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termPhase 3active not recruiting2025609
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyPhase 2completed2025142
The Role of the Amylin Analogue Cagrilintide in Bone MetabolismPhase 1recruiting2025144
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietPhase 1active not recruiting202580
Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintidePhase 3active not recruiting2025300
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityPhase 3active not recruiting2025400
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPhase 3completed20241024
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothPhase 3completed20241023
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExercisePhase 3completed2024189
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboPhase 2completed2024626
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminPhase 3completed2024274
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityPhase 1completed202418
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.Phase 1completed2024178
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightPhase 1completed202434
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightPhase 3completed2024300
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseasePhase 2completed2024270
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 DiabetesPhase 1completed2024158
A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body WeightPhase 1completed202462
A Study of How CagriSema Works on Appetite in People With Excess Body WeightPhase 1completed2024164
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPhase 3active not recruiting20237101
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPhase 3completed20232734
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightPhase 3completed2023809
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightPhase 3completed20231200
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightPhase 3completed2023331
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightPhase 3completed2023300
A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the BodyPhase 1completed202332

Peer-reviewed studies (13)

PaperAuthorsJournalYearType
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1Busetto L et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a studyAroda VR et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 studyBuse JB et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyRosenstock J et al.Lancet (London, England)2026Randomized Controlled Trial
Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous CagrilintideNielsen MJF et al.Clinical pharmacokinetics2026Randomized Controlled Trial
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trialYamauchi T et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1Verma S et al.Hypertension (Dallas, Tex. : 1979)2026Randomized Controlled Trial
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityGarvey WT et al.The New England journal of medicine2025Randomized Controlled Trial
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesDavies MJ et al.The New England journal of medicine2025Randomized Controlled Trial
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participantsGabe MBN et al.Diabetes, obesity & metabolism2024Randomized Controlled Trial
Efficacy and safety of co-administered once-weekly cagrilintide 2·[amount hidden] with once-weekly semaglutide 2·[amount hidden] in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialFrias JP et al.Lancet (London, England)2023Randomized Controlled Trial
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialLau DCW et al.Lancet (London, England)2021Randomized Controlled Trial
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·[amount hidden] for weight management: a randomised, controlled, phase 1b trialEnebo LB et al.Lancet (London, England)2021Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Cagrilintide?

An investigational long-acting amylin analog; CagriSema combines it with semaglutide.

How many registered human trials study Cagrilintide?

The PeptideWhiz trial index lists 44 registered trials for Cagrilintide, the most recent from 2026.

How much published research exists on Cagrilintide?

The PeptideWhiz paper index links 13 PubMed papers to Cagrilintide; by study type, 49 human and 17 animal studies.

Which conditions is Cagrilintide researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Fat loss, obesity & body recomposition, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Neuropathy and CRPS.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research